<DOC>
	<DOC>NCT02017717</DOC>
	<brief_summary>The purpose of the study is to compare the efficacy and safety of nivolumab administered alone versus bevacizumab in patients diagnosed with recurrent glioblastoma (a type of brain cancer, also known as GBM), and to evaluate the safety and tolerability of nivolumab administered alone or in combination with ipilimumab in patients with different lines of GBM therapy.</brief_summary>
	<brief_title>A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients</brief_title>
	<detailed_description>Allocation: Randomized (Cohort 1 and 2), Non-Randomized (Cohorts 1b, 1c and 1d)</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Subjects with histologically confirmed Grade IV malignant glioma Previous treatment with radiotherapy and temozolomide (Cohorts 1, 1b and 2 only) First recurrence of GBM (Cohorts 1, 1b and 2 only) First diagnosis of GBM with resectable disease (Cohorts 1c Part A only) First diagnosis of unmethylated MGMT GBM (Cohort 1d and Cohort 1c Part B only) Karnofsky performance score of 70 or higher More than 1 recurrence of GBM (Cohorts 1, 1b and 2 only) Any recurrence of GBM (Cohorts 1c and 1d only) Presence of extracranial metastatic or leptomeningeal disease Active, known or suspected autoimmune disease Clinically significant cardiovascular disease Prior bevacizumab or other Vascular Endothelial Growth Factor (VEGF) or antiangiogenic treatment (Cohort 2 only)</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>